Arbutus Biopharma (ABUS) Leases (2019 - 2024)
Arbutus Biopharma's Leases history spans 6 years, with the latest figure at $1.0 million for Q4 2024.
- For Q4 2024, Leases fell 25.99% year-over-year to $1.0 million; the TTM value through Dec 2024 reached $1.0 million, down 25.99%, while the annual FY2024 figure was $1.0 million, 25.99% down from the prior year.
- Leases for Q4 2024 was $1.0 million at Arbutus Biopharma, down from $1.1 million in the prior quarter.
- Across five years, Leases topped out at $2.7 million in Q1 2020 and bottomed at $1.0 million in Q4 2024.
- The 5-year median for Leases is $1.9 million (2022), against an average of $1.9 million.
- The largest annual shift saw Leases decreased 11.24% in 2020 before it dropped 25.99% in 2024.
- A 5-year view of Leases shows it stood at $2.4 million in 2020, then fell by 13.01% to $2.1 million in 2021, then fell by 16.63% to $1.7 million in 2022, then dropped by 18.81% to $1.4 million in 2023, then decreased by 25.99% to $1.0 million in 2024.
- Per Business Quant, the three most recent readings for ABUS's Leases are $1.0 million (Q4 2024), $1.1 million (Q3 2024), and $1.2 million (Q2 2024).